Benefits:
-Weight loss
-Blood sugar level stabilisation
-Satiety and appetite suppression
-Improved HbA1c levels
-Once-weekly dosing
-Cardiovascular protection
-Liver fat reduction
Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) developed by Novo Nordisk. It is a synthetic analog of GLP-1, enhanced for stability and prolonged action, allowing once-weekly injections.
It is used for treating:
1. Type 2 diabetes mellitus (T2DM)
2. Obesity/ weight management
GLP-1 is an incretin hormone that binds to GLP-1 receptors in various tissues. It stimulates insulin secretion in a glucose dependent manner. It also suppresses glucagon secretion, which reduces hepatic glucose output. The net result of this is better blood sugar level control without hypoglycemia.
The product also slows gastric emptying, which reduces postprandial glucose spikes and enahnces satiety. Inhibiting caloric intake in this way will result in significant weight loss.
Please notre that semaglutide can result in nausea or constipation. Monitor your dose and titrate up as you assess tolerance.
Semaglutide
Each unit contains 5mg of Semaglutide. Add 5ml of sterile water for injection or bacteriostatic water to reconstitute the product.
0.1ml (10IU)= 0.1mg
The product will last up to 56 days once reconstituted if kept refridgerated.
A beginner dose is 0.25mg (0.25ml) administered subcutneously once per week. This can be tapered up to an intermediate dose of 0.5mg (0.5ml) per week after the first week. An advanced dose would be 1-2mg (1-2ml) per week, though this would be reserved for outliers.
A titration schedule is recommended to taper up and taper down the dose. Here is a sample plan:
Week 1: 0.2mg (0.2ml)
Week 2: 0.3mg (0.3ml)
Week 3:. 0.4mg (0.4ml)
Week 4: 0.5mg (0.5ml)
The user would then continue this dose until the desired level of weight loss had been achieved. They would then progressively taper down by 0.1mg per week until a maintenance dose of 0.1mg per week was established.